Research programme: protein kinase inhibitors - AbbVieAlternative Names: A-443654; A-947864
Latest Information Update: 01 Feb 2013
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Heterocyclic bicyclo compounds; Indazoles; Pyridines; Pyrimidines; Small molecules; Triazoles
- Mechanism of Action Checkpoint kinase 1 inhibitors; Epidermal growth factor receptor antagonists; Insulin-like growth factor-I receptor antagonists; Janus kinase-2 inhibitors; Proto oncogene protein c-akt inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer